EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

,; ,; ,

doi:10.1007/s00125-016-3902-y

Cited by 501 publications

(268 citation statements)

References 151 publications

(58 reference statements)

Supporting

Mentioning

251

Contrasting

Unclassified

Order By: Relevance

“…NAFLD affects 17-46% of adults and occurs in the majority of obese patients, with at least 10% of them presenting with non-alcoholic steatohepatitis (NASH) [5]. While a precise diagnosis of steatosis can be made by quantification of liver fat content using 1 H magnetic resonance spectroscopy, clinical practice still relies on less exact methods such as ultrasound or measurement of serum transaminases.…”

Section: Nafld and Diabetes Mellitusmentioning

confidence: 99%

“…In her review in this symposium series, Hannele Yki-Järvinen proposes a new pathogenic classification of NAFLD: the obese/metabolic, the genetic, and the 'double/triple trouble' forms, which would require different screening and follow-up procedures [6]. Indeed, the new EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease propose a step-wise diagnostic algorithm, which requires joint work-up by diabetologists and hepatologists [5].…”

Section: Nafld and Diabetes Mellitusmentioning

confidence: 99%

See 1 more Smart Citation

The liver in focus

Roden

2016

Diabetologia

View full text Add to dashboard Cite

Section: Nafld and Diabetes Mellitusmentioning

confidence: 99%

Section: Nafld and Diabetes Mellitusmentioning

confidence: 99%

The liver in focus

Roden

2016

Diabetologia

View full text Add to dashboard Cite

“…Fibrosis has been demonstrated to reflect the most important prognostic factor as the degree of fibrosis directly correlates with the prognosis of liver disease [7,8]. Unfortunately, definite diagnosis of the presence of fibrosis and NASH can only be made by liver histology which is rarely performed in NAFLD patients except in selected situations and/or clinical trials [9,10,11,12,13]. Besides ultrasonography, the use of transient elastography is recommended to discover advanced fibrosis; however, in the case of severe obesity this method has certain shortcomings [14].…”

Section: Definition Of Nafldmentioning

confidence: 99%

“…It is commonly defined in non-diabetic NAFLD subjects by the product of fasting glucose (in mmol/l) and insulin (in mU/ml), divided by 22.5 (homeostatic model assessment of insulin resistance (HOMA-IR)), and reflects an accepted parameter for insulin resistance [37]. During follow-up of NAFLD patients, HOMA-IR and worsening of metabolic risk factors might identify patient groups at risk for NASH or fibrosis progression in selected cases [9,10,11,12,13]. Another clinically relevant aspect is the proper interpretation of elevated liver function tests.…”

Section: Clinical Aspects: Nafld Metabolic Syndrome and Type 2 Diabementioning

confidence: 99%

Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome

et al. 2016

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease throughout the world. Pathophysiological insights into this disease have recently illustrated that various factors such as insulin resistance, innate immunity, metabolic inflammation, and the microbiota are of relevance. NAFLD, metabolic syndrome (MS), and type 2 diabetes (T2D) share many pathophysiological aspects, and inflammatory processes in the adipose tissue, gut, and liver have evolved to be of exceptional importance. Most of NAFLD patients are obese and encounter a high risk of developing MS and T2D. NAFLD, however, is also highly common in subjects with MS and T2D. Furthermore, reflecting its nature of a multisystem disease, NAFLD is associated with a high prevalence and incidence of cardiovascular and chronic kidney disease. These facts require screening strategies for MS/T2D in NAFLD patients and vice versa. Thus, the question of cause or effect cannot be answered as MS and NAFLD share many pathomechanisms, and at the time of either diagnosis both frequently coexist. This is also reflected by a global prevalence rate of 25% for both NAFLD and MS. For this reason, it is crucial that physicians are aware of the ‘unholy liaison' between MS, T2D, and NAFLD.

show abstract

“…We examine the evidence and guidelines from Europe, the United States, and the UK’s National Institute for Health and Care Excellence (NICE)8910 for and against the use of specific diagnostic tests. Our approach to the use of liver ultrasound in establishing a diagnosis of hepatic steatosis differs from the recent NICE guidelines,10 but complements British Society of Gastroenterology guidelines 11.…”

mentioning

confidence: 99%

Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults

Byrne

Patel

Scorletti

et al. 2018

BMJ

133

View full text Add to dashboard Cite

At a routine health check arranged by his company, a 52 year-old sedentary male computer programmer was found to have a serum alanine aminotransferase (ALT) concentration of 68 IU/L (normal 0-40 IU/L), and a triglyceride concentration of 1.9 mmol/L. His fasting plasma glucose levels were 5.8 mmol/L and other basic liver, renal and lipid blood tests were normal. He had an unremarkable medical history and took no regular medications, did not smoke and consumed <7 units of alcohol/week. Clinical examination was unremarkable. His body mass index was 29 kg/m 2 ; waist circumference 102 cm and blood pressure 134/88 mmHg.

show abstract

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

Cited by 501 publications

References 151 publications

The liver in focus

The liver in focus

Non-Alcoholic Fatty Liver Disease: Cause or Effect of Metabolic Syndrome

Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults

Contact Info

Product

Resources

About